Preventing Hepatitis B in US Adults Through Vaccination

William Schaffner; Kristin L. Nichol; Arthur L. Reingold

doi:10.1097/IPC.0000000000000685

Preventing Hepatitis B in US Adults Through Vaccination

William Schaffner, Kristin L. Nichol, Arthur L. Reingold

Medicine - Veteran's Administration Medical Center

Research output: Contribution to journal › Article › peer-review

Abstract

Chronic hepatitis B virus (HBV) infection causes substantial morbidity, with up to 40% of infected individuals developing cirrhosis, hepatocellular carcinoma, or liver failure. Approximately 25% of individuals with chronic hepatitis B will die prematurely from these complications. Hepatitis B vaccines are safe and more than 90% effective in preventing infection in at-risk adults, yet only approximately 25% of US adults for whom vaccination is recommended by the Centers for Disease Control and Prevention are vaccinated. The rate of new HBV infections dropped substantially in the United States after the introduction and high uptake of hepatitis B vaccines in infants and children, and the burden of disease has shifted primarily to adults. There has been a resurgence of hepatitis B cases in US adults in recent years, with sharp increases in new cases noted in states highly impacted by the opioid epidemic. Improved hepatitis B vaccination coverage rates in US adults can help slow the rate of acute infections and reduce the reservoir of infection in US adults.

Original language	English (US)
Pages (from-to)	304-312
Number of pages	9
Journal	Infectious Diseases in Clinical Practice
Volume	26
Issue number	6
DOIs	https://doi.org/10.1097/IPC.0000000000000685
State	Published - Nov 1 2018

Bibliographical note

Funding Information:
From the *Vanderbilt University School of Medicine, Nashville, TN; †the National Foundation for Infectious Diseases, Bethesda, MD; ‡University of Minnesota, Minneapolis, MN; and §Berkeley School of Public Health, University of California, Berkeley, CA. Correspondence to: William Schaffner, MD, Vanderbilt University School of Medicine, Village at Vanderbilt, Suite 2600, 1500 21st Ave S, Nashville, TN 37212. E‐mail: william.schaffner@vanderbilt.edu. This publication is based on a National Foundation for Infectious Diseases Roundtable held in June 2018. This activity is supported by an unrestricted educational grant from Dynavax Technologies Corporation. National Foundation for Infectious Diseases policies (http://nfid.org/info/funder-engagement.html) restrict funders from controlling program content. Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved. ISSN: 1056-9103 Abstract: Chronic hepatitis B virus (HBV) infection causes substantial morbidity, with up to 40% of infected individuals developing cirrhosis, hepatocellular carcinoma, or liver failure. Approximately 25% of individuals with chronic hepatitis B will die prematurely from these complications. Hepatitis B vaccines are safe and more than 90% effective in preventing infection in at-risk adults, yet only approximately 25% of US adults for whom vaccination is recommended by the Centers for Disease Control and Prevention are vaccinated. The rate of new HBV infections dropped substantially in the United States after the introduction and high uptake of hepatitis B vaccines in infants and children, and the burden of disease has shifted primarily to adults. There has been a resurgence of hepatitis B cases in US adults in recent years, with sharp increases in new cases noted in states highly impacted by the opioid epidemic. Improved hepatitis B vaccination coverage rates in US adults can help slow the rate of acute infections and reduce the reservoir of infection in US adults.

Publisher Copyright:
© 2018 Wolters Kluwer Health, Inc. All rights reserved.

Keywords

HBV
chronic hepatitis
hepatitis B virus
vaccines

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1097/IPC.0000000000000685

OpenUrl availability

Full text

Cite this

@article{4ba3ab40a39942aca672d5fcfca09ffa,

title = "Preventing Hepatitis B in US Adults Through Vaccination",

abstract = "Chronic hepatitis B virus (HBV) infection causes substantial morbidity, with up to 40% of infected individuals developing cirrhosis, hepatocellular carcinoma, or liver failure. Approximately 25% of individuals with chronic hepatitis B will die prematurely from these complications. Hepatitis B vaccines are safe and more than 90% effective in preventing infection in at-risk adults, yet only approximately 25% of US adults for whom vaccination is recommended by the Centers for Disease Control and Prevention are vaccinated. The rate of new HBV infections dropped substantially in the United States after the introduction and high uptake of hepatitis B vaccines in infants and children, and the burden of disease has shifted primarily to adults. There has been a resurgence of hepatitis B cases in US adults in recent years, with sharp increases in new cases noted in states highly impacted by the opioid epidemic. Improved hepatitis B vaccination coverage rates in US adults can help slow the rate of acute infections and reduce the reservoir of infection in US adults.",

keywords = "HBV, chronic hepatitis, hepatitis B virus, vaccines",

author = "William Schaffner and Nichol, {Kristin L.} and Reingold, {Arthur L.}",

note = "Funding Information: From the *Vanderbilt University School of Medicine, Nashville, TN; †the National Foundation for Infectious Diseases, Bethesda, MD; ‡University of Minnesota, Minneapolis, MN; and §Berkeley School of Public Health, University of California, Berkeley, CA. Correspondence to: William Schaffner, MD, Vanderbilt University School of Medicine, Village at Vanderbilt, Suite 2600, 1500 21st Ave S, Nashville, TN 37212. E‐mail: william.schaffner@vanderbilt.edu. This publication is based on a National Foundation for Infectious Diseases Roundtable held in June 2018. This activity is supported by an unrestricted educational grant from Dynavax Technologies Corporation. National Foundation for Infectious Diseases policies (http://nfid.org/info/funder-engagement.html) restrict funders from controlling program content. Copyright {\textcopyright} 2018 Wolters Kluwer Health, Inc. All rights reserved. ISSN: 1056-9103 Abstract: Chronic hepatitis B virus (HBV) infection causes substantial morbidity, with up to 40% of infected individuals developing cirrhosis, hepatocellular carcinoma, or liver failure. Approximately 25% of individuals with chronic hepatitis B will die prematurely from these complications. Hepatitis B vaccines are safe and more than 90% effective in preventing infection in at-risk adults, yet only approximately 25% of US adults for whom vaccination is recommended by the Centers for Disease Control and Prevention are vaccinated. The rate of new HBV infections dropped substantially in the United States after the introduction and high uptake of hepatitis B vaccines in infants and children, and the burden of disease has shifted primarily to adults. There has been a resurgence of hepatitis B cases in US adults in recent years, with sharp increases in new cases noted in states highly impacted by the opioid epidemic. Improved hepatitis B vaccination coverage rates in US adults can help slow the rate of acute infections and reduce the reservoir of infection in US adults. Publisher Copyright: {\textcopyright} 2018 Wolters Kluwer Health, Inc. All rights reserved.",

year = "2018",

month = nov,

day = "1",

doi = "10.1097/IPC.0000000000000685",

language = "English (US)",

volume = "26",

pages = "304--312",

journal = "Infectious Diseases in Clinical Practice",

issn = "1056-9103",

publisher = "Lippincott Williams and Wilkins",

number = "6",

}

TY - JOUR

T1 - Preventing Hepatitis B in US Adults Through Vaccination

AU - Schaffner, William

AU - Nichol, Kristin L.

AU - Reingold, Arthur L.

N1 - Funding Information: From the *Vanderbilt University School of Medicine, Nashville, TN; †the National Foundation for Infectious Diseases, Bethesda, MD; ‡University of Minnesota, Minneapolis, MN; and §Berkeley School of Public Health, University of California, Berkeley, CA. Correspondence to: William Schaffner, MD, Vanderbilt University School of Medicine, Village at Vanderbilt, Suite 2600, 1500 21st Ave S, Nashville, TN 37212. E‐mail: william.schaffner@vanderbilt.edu. This publication is based on a National Foundation for Infectious Diseases Roundtable held in June 2018. This activity is supported by an unrestricted educational grant from Dynavax Technologies Corporation. National Foundation for Infectious Diseases policies (http://nfid.org/info/funder-engagement.html) restrict funders from controlling program content. Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved. ISSN: 1056-9103 Abstract: Chronic hepatitis B virus (HBV) infection causes substantial morbidity, with up to 40% of infected individuals developing cirrhosis, hepatocellular carcinoma, or liver failure. Approximately 25% of individuals with chronic hepatitis B will die prematurely from these complications. Hepatitis B vaccines are safe and more than 90% effective in preventing infection in at-risk adults, yet only approximately 25% of US adults for whom vaccination is recommended by the Centers for Disease Control and Prevention are vaccinated. The rate of new HBV infections dropped substantially in the United States after the introduction and high uptake of hepatitis B vaccines in infants and children, and the burden of disease has shifted primarily to adults. There has been a resurgence of hepatitis B cases in US adults in recent years, with sharp increases in new cases noted in states highly impacted by the opioid epidemic. Improved hepatitis B vaccination coverage rates in US adults can help slow the rate of acute infections and reduce the reservoir of infection in US adults. Publisher Copyright: © 2018 Wolters Kluwer Health, Inc. All rights reserved.

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Chronic hepatitis B virus (HBV) infection causes substantial morbidity, with up to 40% of infected individuals developing cirrhosis, hepatocellular carcinoma, or liver failure. Approximately 25% of individuals with chronic hepatitis B will die prematurely from these complications. Hepatitis B vaccines are safe and more than 90% effective in preventing infection in at-risk adults, yet only approximately 25% of US adults for whom vaccination is recommended by the Centers for Disease Control and Prevention are vaccinated. The rate of new HBV infections dropped substantially in the United States after the introduction and high uptake of hepatitis B vaccines in infants and children, and the burden of disease has shifted primarily to adults. There has been a resurgence of hepatitis B cases in US adults in recent years, with sharp increases in new cases noted in states highly impacted by the opioid epidemic. Improved hepatitis B vaccination coverage rates in US adults can help slow the rate of acute infections and reduce the reservoir of infection in US adults.

AB - Chronic hepatitis B virus (HBV) infection causes substantial morbidity, with up to 40% of infected individuals developing cirrhosis, hepatocellular carcinoma, or liver failure. Approximately 25% of individuals with chronic hepatitis B will die prematurely from these complications. Hepatitis B vaccines are safe and more than 90% effective in preventing infection in at-risk adults, yet only approximately 25% of US adults for whom vaccination is recommended by the Centers for Disease Control and Prevention are vaccinated. The rate of new HBV infections dropped substantially in the United States after the introduction and high uptake of hepatitis B vaccines in infants and children, and the burden of disease has shifted primarily to adults. There has been a resurgence of hepatitis B cases in US adults in recent years, with sharp increases in new cases noted in states highly impacted by the opioid epidemic. Improved hepatitis B vaccination coverage rates in US adults can help slow the rate of acute infections and reduce the reservoir of infection in US adults.

KW - HBV

KW - chronic hepatitis

KW - hepatitis B virus

KW - vaccines

UR - http://www.scopus.com/inward/record.url?scp=85056564146&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056564146&partnerID=8YFLogxK

U2 - 10.1097/IPC.0000000000000685

DO - 10.1097/IPC.0000000000000685

M3 - Article

AN - SCOPUS:85056564146

SN - 1056-9103

VL - 26

SP - 304

EP - 312

JO - Infectious Diseases in Clinical Practice

JF - Infectious Diseases in Clinical Practice

IS - 6

ER -

Preventing Hepatitis B in US Adults Through Vaccination

Abstract

Bibliographical note

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this